|
|
Article: Medtronic Receives FDA Approval for InSync III Cardiac Resynchronization Therapy System for Heart Failure.
- Article from:
- Business Wire
- Article date:
- February 25, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 25, 2003
New System Features Advanced Patient Monitoring Capabilities and
U.S. Exclusive Sequential Bi-Ventricular Pacing Designed To Improve
The Pumping Power of Failing Hearts
Medtronic, Inc. (NYSE:MDT), today announced that it has received U.S. Food and Drug Administration approval of the InSync(R) III cardiac resynchronization therapy system, the company's third cardiac resynchronization therapy (CRT) system released in the United States following the successful launches of the InSync(R) and InSync(R) ICD systems.
The InSync and InSync III ...